{"id":991675,"date":"2026-08-06T18:33:52","date_gmt":"2026-08-06T22:33:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-reports-record-second-quarter-2026-results-beats-estimates-and-raises-full-year-2026-financial-guidance\/"},"modified":"2026-08-06T18:33:52","modified_gmt":"2026-08-06T22:33:52","slug":"halozyme-reports-record-second-quarter-2026-results-beats-estimates-and-raises-full-year-2026-financial-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-reports-record-second-quarter-2026-results-beats-estimates-and-raises-full-year-2026-financial-guidance\/","title":{"rendered":"HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Total Revenue Increased 48% YOY to $481 million
<\/i>
\n Royalty Revenue Increased 50% YOY to $308 million<\/i>\n <\/p>\n

\n Raises 2026 Financial Guidance Ranges:
<\/i>
\n Total Revenue of $1.835 – $1.910 billion, YOY Growth of 31% – 37%
<\/i>
\n Royalty Revenue of $1.220 – $1.245 billion, YOY Growth of 41% – 43%
<\/i>
\n Adjusted EBITDA of $1.225 – $1.280 billion, YOY Growth of 86% – 95%<\/i>
\n
\n 1
<\/sup>
\n <\/i>
\n Non-GAAP Diluted EPS of $8.65 – $9.00, YOY Growth of 108% – 117%<\/i>
\n
\n 1<\/sup>
\n <\/i>\n <\/p>\n

\n Signed Five New ENHANZE<\/i>
\n
\n \u00ae<\/sup>
\n <\/i>
\n and Hypercon<\/i>
\n
\n \u2122<\/sup>
\n <\/i>
\n Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026<\/i>\n <\/p>\n

\n SAN DIEGO<\/span>, Aug. 6, 2026<\/span> \/PRNewswire\/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the second quarter ended June\u00a030, 2026, and provided an update on its recent corporate activities.<\/p>\n

“We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues,”\u00a0said Dr. Helen Torley, President and Chief Executive Officer. “Total revenue increased 48% year-over-year to $481 million, royalty revenue increased 50% to $308 million and adjusted EBITDA grew 46% to $329 million, reflecting the strength of our differentiated royalty business. Based on these record results, we are raising our full year 2026 financial guidance.”<\/p>\n

“Importantly, we are delivering on both our near-term and long-term growth objectives. The ENHANZE value proposition is attracting new partners and additional products from our current partners. We expanded our royalty revenue opportunity by signing five new ENHANZE and Hypercon collaborations through July, including agreements with Vertex, Oruka, GSK, Incyte and an undisclosed partner who is the first to license ENHANZE for a nucleic acid therapeutic. We have also demonstrated our commitment to returning significant capital to shareholders, repurchasing $333 million of shares in 2Q 2026, at an average price of $69.30. Overall, these results illustrate our continued ability to create multiple waves of revenue opportunities that will drive long-term shareholder value,” concluded Dr. Torley.<\/p>\n

\n Second Quarter Corporate Highlight:<\/b>\n <\/p>\n